UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40556 THE GLIMPSE GROUP, INC. (Exact name of registrant as specified in its charter) Nevada 81-2958271 (State or other jurisdic ...

FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 | Delaware | 001-39318 | 46-3973463 | | --- | --- | --- | | (State or Other Jurisdiction | (Commission | (IRS Empl ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Date of Report (date of earliest event reported): May 15, 2025 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) (State or other jurisdiction of incorporation) Delaware 001-38323 82-3074668 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 (Commission File Number) (IRS Employer Identification No.) 4870 Sadler Road, Ste 300 Glen Allen, VA 23060 (Address of principa ...

Exhibit 99.1 The Glimpse Group Reports Q3 Fiscal Year 2025 Financial Results Reaf irm Revenues and Second Consecutive Quarter of Positive Cash Flow NEW YORK, NY, May 15, 2025 - The Glimpse Group, Inc. ("Glimpse") (NASDAQ: VRAR; FSE: 9DR), a diversified Immersive Technology platform company providing enterprise-focused Virtual Reality ("VR"), Augmented Reality ("AR") and Spatial Computing software and services, provided financial results for its third quarter fiscal year 2025, ended March 31, 2025 ("Q3 FY '2 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO (Exact name of Registrant as specified in its Charter) (State or other jurisdiction of incorporation or organization) 7683 SE 27 Street, Suite 481 Mercer I ...

Revenue Growth - Total revenue increased by $501,148, or 212%, from $236,677 for the three months ended March 31, 2024, to $737,825 for the same period in 2025, driven by a 38% increase in locations using services[99]. - Cloud video surveillance subscriptions increased by 79%, remote guarding increased by 164%, hardware sales increased by 241%, and installation labor sales increased by 397% compared to the same period in 2024[99]. Expenses - Cost of goods sold increased by $154,242, or 61%, from $253,232 for the three months ended March 31, 2024, to $407,473 for the same period in 2025[103]. - General and administrative expenses increased by 114% for the three months ended March 31, 2025, primarily due to a one-time bonus of $323,000 paid to employees[107]. - Research and development expenses increased by 71% for the three months ended March 31, 2025, with payroll increasing by $237,000 due to a one-time bonus[108]. Net Loss - Net loss for the three months ended March 31, 2025, was $2.5 million, compared to a net loss of $1.7 million for the same period in 2024, representing a 46% increase in loss[111]. Cash Position - Cash and cash equivalents at the end of the period were $6.845 million for the three months ended March 31, 2025, compared to $(1.028) million for the same period in 2024[115]. - Net cash provided by financing activities was $9.4 million for the three months ended March 31, 2025, compared to approximately $0 for the same period in 2024[120]. - As of March 31, 2025, the company had approximately $6.9 million in cash and $6.8 million in working capital, expecting current cash to fund operations through at least Q1 2026[126]. Future Outlook - The company anticipates entering additional markets in 2025 and 2026, focusing on expanding its customer base in the property management space[89]. - The company expects to incur additional losses for the foreseeable future as it continues to expand and develop new products and services[125]. - The company has an accumulated deficit of approximately $43.4 million as of March 31, 2025, and expects to continue incurring operating losses and negative cash flows for the foreseeable future[128]. - The Series 2 Purchase Agreement and Equity Purchase Agreement may provide necessary funding for the next 12 months, but their execution is subject to conditions beyond the company's control[127]. Financial Management - The company has a planning and budgeting process to monitor operating cash requirements, including capital expenditures, general and administrative costs, and public company operating costs[129]. - Contractual obligations primarily relate to operating lease obligations, capital lease obligations, and insurance obligations, which are generally terminable after a notice period[130]. - The company does not have any long-term debt or significant long-term liabilities as of the reporting period[131]. Regulatory Status - The company is classified as an "emerging growth company" under the JOBS Act, allowing it to take advantage of certain reporting exemptions[133]. - The company has elected to use an extended transition period for complying with new accounting standards, which may affect the comparability of its financial statements[134]. - The company is not required to provide certain disclosures related to executive compensation due to its status as an emerging growth company[138]. - The company evaluates its accounting estimates and assumptions on an ongoing basis, which may impact reported amounts of assets, liabilities, revenue, and expenses[140].

Financial Performance - Net loss for Q1 2025 was $2.3 million, or $0.23 per share, compared to a net loss of $4.0 million, or $0.39 per share, in Q1 2024[13] - Total operating expenses decreased to $2,341 million in Q1 2025 from $4,158 million in Q1 2024, representing a reduction of 43.7%[23] - Net loss narrowed to $2,301 million in Q1 2025 compared to a net loss of $3,956 million in Q1 2024, reflecting an improvement of 42%[23] - Net loss per common share improved to $(0.23) in Q1 2025 from $(0.39) in Q1 2024, a reduction of 41%[23] Expenses - Research and development (R&D) expenses for Q1 2025 were $1.4 million, down from $3.0 million in Q1 2024, primarily due to reduced personnel costs and clinical study timing[12] - General and administrative (G&A) expenses for Q1 2025 were $1.0 million, compared to $1.2 million in Q1 2024, mainly due to lower insurance costs[12] - Research and development expenses were $1,360 million in Q1 2025, down from $2,950 million in Q1 2024, a decrease of 53.9%[23] Cash and Assets - Unrestricted cash as of March 31, 2025, was $6.9 million, down from $9.9 million as of December 31, 2024[14] - Cocrystal's total assets as of March 31, 2025, were $10.7 million, down from $13.5 million as of December 31, 2024[21] Market and Product Development - Cocrystal's oral pan-viral protease inhibitor CDI-988 has shown superior broad-spectrum antiviral activity against GII.17 strains, the most prevalent strain in the U.S. and Europe for 2024-2025[15] - The global COVID-19 therapeutics market is projected to exceed $16 billion annually by the end of 2031[11] - Cocrystal is preparing to launch a U.S. human challenge study for CDI-988, a critical step in advancing this therapy[2] - The company reported favorable safety and tolerability results from the Phase 1 study of CDI-988, with plans to report topline results in Q2 2025[15] Other Financial Metrics - Interest income increased to $37 million in Q1 2025 from $220 million in Q1 2024, indicating a significant decline[23] - Foreign exchange gain was $3 million in Q1 2025, compared to a loss of $(18) million in Q1 2024, showing a positive turnaround[23] - The weighted average number of common shares remained constant at 10,174 million for both Q1 2025 and Q1 2024[23] Norovirus Impact - The annual burden of norovirus in the U.S. is estimated at $10.6 billion, with noroviruses responsible for approximately 21 million cases annually[8]

Exhibit 99.1 Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates FOR IMMEDIATE RELEASE DALLAS—(BUSINESS WIRE)— May 15, 2025 — Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging its proprietary RADR artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced operational highlights and financial results for the first quarter 2025 ended Ma ...

Antiviral Development - Cocrystal Pharma is focused on developing antiviral therapeutics for norovirus, coronavirus, and influenza, utilizing structure-based technologies[91] - The company has received authorization for a Phase 2a human challenge study with oral CC-42344 for influenza A, completing enrollment of 78 subjects[97] - CC-42344 demonstrated excellent in vitro antiviral activity against various influenza A strains, including those resistant to Tamiflu® and Xofluza®[95] - CDI-988, a novel protease inhibitor, is being evaluated for safety and tolerability in a Phase 1 study, with favorable results reported from single-ascending dose cohorts[101][103] - Noroviruses cause an estimated 21 million cases of acute gastroenteritis annually in the U.S., with no effective treatment currently available[108] - The company is developing broad-spectrum influenza antivirals targeting replication enzymes of seasonal and pandemic influenza A and B strains[100] - Cocrystal Pharma's research and development efforts are primarily focused on addressing unmet medical needs in viral diseases[93] - The global HCV market is significant, with an estimated 58 million people having chronic HCV infections, and the company aims to develop ultra-short treatment regimens of four to six weeks[116][117] - CC-31244 is a potential best-in-class pan-genotypic inhibitor for HCV, with favorable safety results from previous studies and ongoing efforts to find a partner for further development[118][119] Financial Performance - Total research and development expenses decreased from $2,950,000 in Q1 2024 to $1,360,000 in Q1 2025, a reduction of approximately 54%[121] - General and administrative expenses decreased from $1,208,000 in Q1 2024 to $981,000 in Q1 2025, a reduction of about 19%[123] - Net loss for Q1 2025 was $2,301,000, compared to a net loss of $3,956,000 in Q1 2024, representing a decrease in loss of approximately 42%[127] - Net cash used in operating activities decreased from $4,503,000 in Q1 2024 to $2,939,000 in Q1 2025, a reduction of about 35%[128] - The company had $6,921,000 in unrestricted cash as of March 31, 2025, which is expected to be insufficient to cover working capital needs for the next 12 months[131] - Interest income decreased from $220,000 in Q1 2024 to $37,000 in Q1 2025, a decline of approximately 83%[124] - Foreign exchange gain of $3,000 was recorded in Q1 2025, compared to a foreign exchange loss of $18,000 in Q1 2024[125] - No cash was used for investing activities in Q1 2025, compared to $8,000 used in Q1 2024[129] - The company has not achieved annual profitability since inception and continues to incur operating losses[133] - The company intends to fund future operations through additional private or public equity offerings and strategic partnerships[136] Study Protocol and Adjustments - The company is in discussions to potentially amend the Phase 2a study protocol for CC-42344 due to low influenza infection rates among participants[98]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission file number: 001-37673 WORKHORSE GROUP INC. (Exact name of registrant as specified in its charter) Nevada 26-1394771 (State or other ...